BioNexus Gene Lab Corp.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $3.8M
- Price
- $1.59
- % Change (Daily % change from the live per-ticker quote feed.)
- +0.22%
- Volume
- 1.0K
About
BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries. Its subsidiary, Chemrex Corporation Sdn. Bhd., specializes in the wholesale distribution of chemical raw material products across Malaysia, Indonesia, Vietnam, and other nations within Southeast Asia. These essential chemicals are utilized in the manufacturing of a wide array of products, including handrails, bench tops, components for the automotive and aerospace industries, cleanroom panels, and various instruments. Additionally, through its other subsidiary, BioNexus Gene Lab Sdn. Bhd., the company is involved in the development and provision of non-invasive liquid biopsy tests, designed for the early detection of biomarkers.
Quick stats
Shares outstanding2.4M
Computed float1.7M
Float / shares71.0%
Key info
SectorIndustrials
IndustryIndustrial - Distribution
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001737523
AI Summary
AI-generated1/3
standardbullishoperations update
BioNexus Advances VitaGuard™ Southeast Asia Rollout Following China Working Visit
BioNexus is advancing the commercial rollout of its licensed VitaGuard liquid-biopsy platform in Southeast Asia following a strategic working visit to the Tongshu Gene group in China.
The visit focused on technical planning and implementation requirements for the region, which covers a population of over 680 million, with BioNexus targeting initial deployments in select medical hubs during 2026.
BioNexus holds exclusive commercial rights in ten Southeast Asian markets and a 15% equity stake in licensor Fidelion, targeting a sub-$300 cost profile to drive adoption in cost-sensitive healthcare systems.
Red flags
- No definitive agreement executed for Fidelion's partnerships outside Southeast Asia
- Revenue generation dependent on completing laboratory validation and regulatory approvals